NDAORALTABLETPriority Review
Approved
Jul 2019
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
5/8 — Partial
Priority Review
XPOVIO (selinexor) by Mthera Pharma is nuclear export inhibitors [moa]. First approved in 2019.
Drug data last refreshed 17h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
XPOVIO (selinexor) is an oral small-molecule nuclear export inhibitor approved in July 2019 for hematologic malignancies. It works by blocking XPO1, a nuclear export protein, causing selective retention of tumor suppressors in cancer cell nuclei and triggering apoptosis. The drug represents a novel mechanism targeting nuclear-cytoplasmic transport dysregulation in cancer.
$0.086BPart D
Peak8.8 years to LOEProduct is at peak commercial maturity with $86M in Part D spending; teams are focused on maintaining market position and maximizing adoption within approved indications.
Mechanism of Action
Nuclear Export Inhibitors
Pharmacologic Class:
Nuclear Export Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Imlunestrant/Abemaciclib/Selinexor in Ovarian and Endometrial
Started Dec 2026
60 enrolled
Low Grade Ovarian Serous AdenocarcinomaEndometrial Cancer
Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias
Started Oct 2026
26 enrolled
MyelofibrosisPost-polycythemia Vera MyelofibrosisPost-essential Thrombocythemia Myelofibrosis
Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma
Started May 2026
62 enrolled
Relapse Multiple MyelomaRefractory Multiple Myeloma
Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma
Started Mar 2026
20 enrolled
Multiple Myeloma
A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma
Started Nov 2025
228 enrolled
Relapsed or Refractory Multiple Myeloma
Worked on XPOVIO at Mthera Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.